Found 358 results
Author Keyword [ Title(Desc)] Type Year
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
A. du Bois, Weber, B., Rochon, J., Meier, W., Goupil, A., Olbricht, S., Barats, J. - C., Kuhn, W., Orfeuvre, H., Wagner, U., Richter, B., Lueck, H. - J., Pfisterer, J., Costa, S., Schröder, W., Kimmig, R., and Pujade-Lauraine, E., Addition of epirubicin as a third drug to carboplatin-paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup trial. , J Clin Oncol, vol. 24, no. 7, pp. 1127-35, 2006.
E. Eisenhauer, Addressing unanswered questions in ovarian cancer trial methodology: follow-up of the 2004 Baden-Baden Gynecologic Cancer Intergroup meeting., Int J Gynecol Cancer, vol. 18 Suppl 1, pp. 74-5, 2008.
S. M. de Boer, Powell, M. E., Mileshkin, L. R., Katsaros, D., Bessette, P., Haie-Meder, C., Ottevanger, P. B., Ledermann, J. A., Khaw, P., Colombo, A., Fyles, A., Baron, M. - H., Jürgenliemk-Schulz, I. M., Kitchener, H. C., Nijman, H. W., Wilson, G., Brooks, S., Carinelli, S., Provencher, D. M., Hanzen, C., Lutgens, L. C. H. W., Smit, V. T. H. B. M., Singh, N., Do, V., D'Amico, R., Nout, R. A., Feeney, A., Verhoeven-Adema, K. W., Putter, H., and Creutzberg, C. L., Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial., Lancet Oncol, 2018.
H. C. Kitchener, Adjuvant chemotherapy improves survival after resection of stage 1 ovarian cancer., Cancer Treat Rev, vol. 31, no. 4, pp. 323-7, 2005.
G. Mangili, Scarfone, G., Gadducci, A., Sigismondi, C., Ferrandina, G., Scibilia, G., Vigano, R., Tateo, S., Villa, A., and Lorusso, D., Is adjuvant chemotherapy indicated in stage I pure immature ovarian teratoma (IT)? A multicentre Italian trial in ovarian cancer (MITO-9), Gynecol Oncol, vol. 119, pp. 48-52, 2010.
P. Blake, Swart, A. Marie, Orton, J., Kitchener, H. C., Whelan, T., Lukka, H., Eisenhauer, E., Bacon, M., Tu, D., Parmar, M. K. B., Amos, C., Murray, C., and Qian, W., Adjuvant external beam radiotherapy in the treatment of endometrial cancer (MRC ASTEC and NCIC CTG EN.5 randomised trials): pooled trial results, systematic review, and meta-analysis., Lancet, vol. 373, no. 9658, pp. 137-46, 2009.
S. C. Dowdy and Glaser, G. E., Adjuvant therapy for women with high-risk endometrial carcinoma., Lancet Oncol, 2018.
R. C. Young, Brady, M. F., Nieberg, R. K., Long, H. J., Mayer, A. R., Lentz, S. S., Hurteau, J. A., and Alberts, D. S., Adjuvant treatment for early ovarian cancer: a randomized phase III trial of intraperitoneal 32P or intravenous cyclophosphamide and cisplatin–a gynecologic oncology group study, J Clin Oncol, vol. 21, pp. 4350-5, 2003.
D. G. Allen, Baak, J., Belpomme, D., Berek, J. S., Bertelsen, K., Huinink, W. W. ten Bok, van der Burg, M. E. L., Calvert, A. H., Conte, P. F., and Dauplat, J., Advanced epithelial ovarian cancer: 1993 consensus statements., Ann Oncol, vol. 4 Suppl 4, pp. 83-8, 1993.
J. S. Berek, Bertelsen, K., du Bois, A., Brady, M. F., Carmichael, J., Eisenhauer, E., Gore, M. E., Grenman, S., Hamilton, T. C., Hansen, S. W., Harper, P. G., Horvath, G., Kaye, S. B., Lück, H. J., Lund, B., McGuire, W. P., Neijt, J. P., Ozols, R. F., Parmar, M. K. B., Piccart, M. J., van Rijswijk, R., Rosenberg, P., Rustin, G. J. S., Sessa, C., and Willemse, P. H., Advanced epithelial ovarian cancer: 1998 consensus statements., Ann Oncol, vol. 10 Suppl 1, pp. 87-92, 1999.
J. B. Vermorken, Huinink, W. W. ten Bok, Eisenhauer, E., Favalli, G., Belpomme, D., Conte, P. F., and Kaye, S. B., Advanced ovarian cancer. Carboplatin versus cisplatin., Ann Oncol, vol. 4 Suppl 4, pp. 41-8, 1993.
G. J. S. Rustin, van der Burg, M. E. L., and Berek, J. S., Advanced ovarian cancer. Tumour markers., Ann Oncol, vol. 4 Suppl 4, pp. 71-7, 1993.
Advanced ovarian cancer: where do we stand and where do we go? Workshop proceedings. June 15-19, 1993, Elsinore, Denmark., Ann Oncol, vol. 4 Suppl 4, pp. 1-88, 1993.
S. Sagae, Monk, B. J., Pujade-Lauraine, E., Gaffney, D. K., Narayan, K., Ryu, S. Young, McCormack, M., Plante, M., Casado, A., Reuss, A., Chávez-Blanco, A., Kitchener, H. C., Nam, B. - H., Jhingran, A., Temkin, S., Mileshkin, L. R., Berns, E. M. J. J., Scholl, S., Doll, C., Abu-Rustum, N. R., Lecuru, F., and Small, W., Advances and Concepts in Cervical Cancer Trials: A Road Map for the Future., Int J Gynecol Cancer, vol. 26, no. 1, p. 207, 2016.
F. Trillsch, Mahner, S., Woelber, L., Vettorazzi, E., Reuss, A., Ewald-Riegler, N., de Gregorio, N., Fotopoulou, C., Schmalfeldt, B., Burges, A., Hilpert, F., Fehm, T., Meier, W., Hillemanns, P., Hanker, L., Hasenburg, A., Strauss, H. G., Hellriegel, M., Wimberger, P., Baumann, K. H., Keyver-Paik, M. D., Canzler, U., Wollschlaeger, K., Forner, D., Pfisterer, J., Schröder, W., Muenstedt, K., Richter, B., Kommoss, F., Hauptmann, S., and du Bois, A., Age-dependent differences in borderline ovarian tumours (BOT) regarding clinical characteristics and outcome: Results from a sub-analysis of the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) ROBOT study, Ann Oncol, vol. 25, pp. 1320-7, 2014.
D. Shaw, Clamp, A. R., and Jayson, G. C., Angiogenesis as a target for the treatment of ovarian cancer, Curr Opin Oncol, vol. 25, pp. 558-65, 2013.
F. T. Roncolato, O'Connell, R., Joly, F., Lanceley, A., Hilpert, F., Okamoto, A., Aotani, E., Pignata, S., Donnellan, P. P., Oza, A. M., Åvall-Lundqvist, E., Berek, J. S., Sjoquist, K. Marie, Gillies, K., Butow, P., Stockler, M. R., King, M. Trudy, and Friedlander, M. Leonard, Baseline predictors of early treatment failure in patients with platinum resistant/refractory (PRR) and potentially platinum sensitive (PPS ≥ 3) recurrent ovarian cancer (ROC) receiving ≥ 3 lines of chemotherapy: The GCIG Symptom Benefit Study (SBS).. 2015.
E. Pujade-Lauraine, Hilpert, F., Weber, B., Reuss, A., Poveda, A. M., Kristensen, G. B., Sorio, R., Vergote, I. B., Witteveen, P., Bamias, A., Pereira, D., Wimberger, P., Oaknin, A., Mirza, M. Raza, Follana, P., Bollag, D., and Ray-Coquard, I., Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial., J Clin Oncol, vol. 32, no. 13, p. 1308, 2014.
A. M. Poveda, Selle, F., Hilpert, F., Reuss, A., Savarese, A., Vergote, I. B., Witteveen, P., Bamias, A., Scotto, N., Mitchell, L., and Pujade-Lauraine, E., Bevacizumab Combined With Weekly Paclitaxel, Pegylated Liposomal Doxorubicin, or Topotecan in Platinum-Resistant Recurrent Ovarian Cancer: Analysis by Chemotherapy Cohort of the Randomized Phase III AURELIA Trial., J Clin Oncol, vol. 33, no. 32, p. 3838, 2015.
R. T. Penson, Huang, H. Q., Wenzel, L. B., Monk, B. J., Stockman, S., Long, H. J., Ramondetta, L. M., Landrum, L. M., Oaknin, A., Reid, T. J. A., Leitao, M. M., Method, M., Michael, H., and Tewari, K. S., Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomised, phase 3 trial (NRG Oncology-Gynecologic Oncology Group protocol 240)., Lancet Oncol, vol. 16, no. 3, pp. 301-11, 2015.
P. Harter, Johnson, T., Berton-Rigaud, D., Park, S. - Y., Friedlander, M. Leonard, Del Campo, J. M., Shimada, M., Forget, F., Mirza, M. R., Colombo, N., Zamagni, C., Chan, J. K., Imhof, M., Herzog, T. J., O'Donnell, D., Heitz, F., King, K., Stinnett, S., Barrett, C., Jobanputra, M., Xu, C. - F., and du Bois, A., BRCA1/2 mutations associated with progression-free survival in ovarian cancer patients in the AGO-OVAR 16 study., Gynecol Oncol, vol. 140, no. 3, pp. 443-9, 2016.